Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 2011

View Archived Issues

Polyphor prepares novel chemokine CCR10 receptor antagonists

New deuterated HCV NS5B inhibitors presented by Roche

Preliminary phase II data show activity of quizartinib in FLT3-ITD+ AML

MMP-23 level in melanoma tumors correlates with response to immune biologics

Zydux-Cadila patents novel factor Xa inhibitors

Sanofi patents new inhibitors of PDGF-R-beta and FLT-3

New antiviral agents disclosed by Hetero Research Foundation

Encouraging survival data from phase II bavituximab combination trial in NSCLC

PharmaGap reports significant efficacy improvement for enhanced GAP-107B8

ARIAD reports preclinical data on anticancer candidate AP-26113

NeurogesX completes enrollment in phase II NGX-1998 trial in postherpetic neuralgia

Phase I data support safety and possible activity of Rheumavax in rheumatoid arthritis

MR-1 Fab' PEG shows promise in murine model of arthritis

SRX-246 is safe and well tolerated in phase I study

Phase I results reported on renin inhibitor VTP-27999

Clinical development begins for Inviragen's INV-21 vaccine for hand, foot and mouth disease

Alkermes begins ALKS-5461 study in treatment-resistant depression

European Commission approves Cinryze for hereditary angioedema

Aradigm reports promising data from ORBIT-1 trial in non-CF bronchiectasis

Pearl Therapeutics begins new clinical studies of bronchodilator combination product

Nycomed gains Asia-Pacific marketing rights to Bonviva from Roche

Cordis to exit drug-eluting stent market

Activus and Gifu Pharmaceutical University to collaborate on Activus Pure Nanoparticle Technology

Alexion to conduct clinical study of Soliris in STEC-HUS in response to EHEC outbreak in Germany

Ischemix's phase IIa trial of cardioprotective drug candidate CMX-2043 meets primary endpoint

Novo Nordisk issues reminder of risks associated with Victoza